Dear Editor,

I read with interest the study by Zampogna et al. [1], where the authors described their clinical experience with a cohort of patients recovering from COVID-19 enrolled in a rehabilitation programme. As highlighted by the authors, at the beginning of the pandemic very little information was available regarding the rehabilitative treatment in such an unprecedented situation apart from practical recommendations released by scientific/professional societies [2]. Thanks to those recommendations, healthcare professionals involved in the rehabilitation treatment of patients with COVID-19 have found a scientific basis for approaching patients in both acute and subacute care settings. Since the first wave of the pandemic occurred in early 2020, only a small number of studies discussing physiotherapy practice have been published when compared with thousands of articles in the medical field. From a certain point of view, the study by Zampogna et al. [1] can be considered one of the firsts including a considerable number of patients via a retrospective observational design. Another previously published study by Jiandani et al. [3] investigated the effects of rehabilitation in COVID-19 in a broader population using the same study design. If we would reflect on the paucity of studies discussing rehabilitation in COVID-19, we have to consider the following arguments: (1) it seems that observational designs are encountering difficulties being published probably because they are typically considered a type of research bearing the bias of being uncontrolled in nature. (2) We all as clinicians, researchers, authors, reviewers, and editors are aware of the increasing interest mounting on the rehabilitation field, but we observe that this topic – at the time of writing – is underestimated. (3) Is rehabilitation considered a secondary therapeutic line of treatment not deserving the same attention which is given to other disciplines?

All these hypotheses should be considered when reading the study by Zampogna et al. [1] who have produced research containing valuable insights. In fact, from their article, it can be gathered – among the various information available – that patients can afford a rehabilitation treatment (whose intensity varied according to their clinical conditions) when having a PaO2/FiO2 ratio ≥310 mm Hg, after a long hospitalization ≥33.5 days, and being able to walk ≥250 m at the 6-min walking test after having attended a rehabilitation programme [1]. Let me say that these are not secondary aspects. All these pieces of information are available from a retrospective observational study design.

Another message that can be taken from the experience of Zampogna et al. [1] concerns the obvious reflection on the impossibility to conduct studies with control populations because, in that case, patients could be exposed to the risk of not receiving rehabilitation.

The study by Zampogna et al. [1] provides helpful insights to be transferred to the real world. It could contribute to inspiring authors, reviewers, and editors in producing, revising, and publishing more pieces of research considering that observational studies of rehabilitation in COVID-19 are probably the unique viable option if we want to expand our knowledge in this specific matter.

The author has no conflicts of interest to declare.

No funding was received.

1.
Zampogna
E
,
Paneroni
M
,
Belli
S
,
Aliani
M
,
Gandolfo
A
,
Visca
D
,
Pulmonary rehabilitation in patients recovering from COVID-19
.
Respiration
.
2021
;
100
(
5
):
416
22
.
2.
Polastri
M
,
Brini
S
,
Ghetti
A
,
Lama
A
.
Recommendations form scientific/professional societies: an essential support for physiotherapy in patients with COVID-19
.
Int J Ther Rehabil
.
2020
;
27
(
4
):
1
3
.
3.
Jiandani
MP
,
Salagre
SB
,
Kazi
S
,
Iyer
S
,
Patil
P
,
Khot
WY
,
Preliminary observations and experiences of physiotherapy practice in acute care setup of COVID 19: a retrospective observational study
.
J Assoc Physicians India
.
2020
;
68
(
10
):
18
24
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.